Post-gemcitabine therapy for patients with advanced pancreatic cancer – A comparative review of randomized trials evaluating oxaliplatin- and/or irinotecan-containing regimens

Autor: Vogel, Arndt, Ciardiello, Fortunato, Hubner, Richard A., Blanc, Jean-Frédéric, Carrato, Alfredo, Yang, Yoojung, Patel, Dipen A., Ektare, Varun, de Jong, Floris A., Gill, Sharlene

Publikováno v: In Cancer Treatment Reviews November 2016 50:142-147

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Evaluating Drug Cost per Response with SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus

Autor: Lopez, Janice M.S., Macomson, Brian, Ektare, Varun, Patel, Dipen, Botteman, Marc

The sodium-glucose cotransporter 2 (SGLT2) inhibitors, which include canagliflozin, dapagliflozin, and empagliflozin, represent a new class of antihyperglycemic agents. Few studies have assessed their cost per response, with "cost per response" being

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5b4d5b0d1a3fc4425831471dcfdc8043
https://europepmc.org/articles/PMC4636281/

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Clinical and economic analysis of outcomes of dose tapering or withdrawal of tumor necrosis factor-α inhibitors upon achieving stable disease activity in rheumatoid arthritis patients.

Autor: Aletaha D; Division of Rheumatology, Department of Internal Medicine, Medical University of Vienna, Vienna, Austria., Snedecor SJ; Pharmerit International, Bethesda, MD., Ektare V; Pharmerit International, Bethesda, MD., Xue M; Pharmerit International, Bethesda, MD., Bao Y; AbbVie Inc., North Chicago, IL, USA., Garg V; AbbVie Inc., North Chicago, IL, USA.

Publikováno v: ClinicoEconomics and outcomes research : CEOR [Clinicoecon Outcomes Res] 2017 Jul 28; Vol. 9, pp. 451-458. Date of Electronic Publication: 2017 Jul 28 (Print Publication: 2017).